Therapeutic Management

One of the main aims of treatment in T2D is to reduce the risk of vascular complications. Glucose control helps to reduce microvascular complications, but its impact on macrovascular outcomes remains uncertain. Patients with T2D may therefore require additional CV risk factor control. 
 

  • view presentation
    Practical guidance on the use of SGLT2 inhibitors in patients with T2D during Ramadan

    This module summarises current practical guidance, evidence and recomm

  • view presentation
    Diabetes and COVID-19

    This module summarises recent guidance for healthcare professionals

  • view presentation
    Patient case study - Patient with PAD at risk of CV events

    PAD is a complication of T2D and a predictor of CV events. This intera

  • view presentation
    Patient case study - Patient with hypoglycaemia at risk of CV and kidney events

    Patients with T2D have a risk of CV and kidney events. This interactiv

  • view presentation
    Evolving evidence-based recommendations in T2D

    This module summarises recent changes to global diabetes, cardiovascul

  • view presentation
    Evolution of glucose-lowering therapies

    This module summarises evidence from cardiovascular outcomes trials (C

  • view presentation
    Interpreting real-world evidence

    Numerous sources of clinical data are used to inform clinical practice

  • view presentation
    Use of SGLT2 inhibitors in primary care

    This module outlines SGLT2 inhibitor CVOT data, safety informatio

  • view presentation
    Managing CV risk in type 2 diabetes

    Type 2 diabetes is a strong independent risk factor for cardiovascular